Welcome to Gedeon Richter PregLem

Pioneering first-in-class medical treatments in reproductive medicine

Learn more

Developing first-in-class therapies for gynaecologic conditions with significant unmet needs

Learn more

Changing the rules of treatment, drug performance and innovations

Learn more

Preserving the integrity of womanhood

Learn more

aboutGedeon Richter PregLem SA is a Swiss-based speciality biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem is a member of the Richter Group.

PregLem’s activities focus on developing therapies for gynaecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life:


(Ulipristal Acetate/PGL4001)

Completed Ph III
EMA approval as a pre-operative treatment of moderate to severe symptoms of uterine fibroids received in February 2012

(Steroid Sulfatase Inhibitor, STS-I)

Mild or Moderate Endometriosis: Phase IIa

(c-Jun-N-Terminal Kinase Inhibitor (JNK-I), Bentamapimod)

Inflammatory Endometriosis: Phase IIa / Proof of Concept (POC)
Adhesions: Phase IIa/Proof of Concept (POC)

(Somatostatin Antagonist, SST-ATG)

Ovarian Reserve Modulation: Pre-clinical development


Latest news

Submit your e-mail address to receive news updates by email

Register now

Press room

Visit now

European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)

Budapest, Hungary – 28 May 2015 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted approval for the intermittent use of Esmya® 5mg in the long term management of uterine fibroids. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on 23 April 2015 and is applicable for all Member States in the European Economic Area.